Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05979415 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
A Phase 2 study, sponsored by Alexza Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05979415: Clinical Trial Phase 2 study, sponsored by Alexza Pharmaceuticals.
NCT05979415 is a Phase 2 study that was terminated before completion, run by Alexza Pharmaceuticals. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05979415, a Phase 2 study, was terminated before completion, sponsored by Alexza Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
Primary Outcome
The MDS-UPDRS is a revision of the Unified Parkinson's Disease Rating Scale (UPDRS) and was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications.
Interventions
- DRUG Apomorphine Cartridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-09-27 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 2 |
Why NCT05979415 stopped before completion
NCT05979415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Apomorphine Cartridge is the first listed.
NCT05979415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05979415 about?
NCT05979415 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes". This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
What is the current status of trial NCT05979415?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-09-27. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05979415?
The interventions under investigation include: Apomorphine Cartridge (DRUG).
Who is sponsoring clinical trial NCT05979415?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05979415's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI